Fairscale Capital’s AstraZeneca AZN Stock Holding History

Fairscale Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.1K	Hold	106	–	–	0.01%	280
2026 Q1	$20.9K	Hold	106	–	–	0.01%	273
2025 Q4	$19.5K	Hold	106	–	–	0.01%	270
2025 Q3	$16.3K	Hold	106	–	–	0.01%	297
2025 Q2	$15.5K	Hold	106	–	–	0.01%	296
2025 Q1	$15.6K	Hold	106	–	–	0.01%	234
2024 Q4	$13.9K	Hold	106	–	–	0.01%	241
2024 Q3	$16.5K	Hold	106	–	–	0.01%	238
2024 Q2	$16.7K	Buy	+106	New	+$16K	0.01%	236

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fairscale Capital's AZN Position: Q2 2026 in Review

Fairscale Capital held its AstraZeneca (AZN) position steady in Q2 2026 at 106 shares worth $20.1K. The position accounts for 0.01% of the portfolio, ranked #280.

Fairscale Capital first reported a position in AZN in Q2 2024 and has held it in 9 quarters since. The position peaked at $20.9K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Fairscale Capital held 106 shares of AstraZeneca worth $20.1K as of Q2 2026.
Fairscale Capital left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Fairscale Capital's portfolio in Q2 2026, its #280 holding.
Fairscale Capital first reported a position in AstraZeneca in Q2 2024 and has held it in 9 quarters since.
Fairscale Capital's AstraZeneca position peaked at $20.9K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.